An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN)

Mariko DeWire*, Maryam Fouladi, David C. Turner, Cynthia Wetmore, Cynthia Hawkins, Carmen Jacobs, Ying Yuan, Diane Liu, Stewart Goldman, Paul Fisher, Michael Rytting, Eric Bouffet, Yasmin Khakoo, Eugene I. Hwang, Nicholas Foreman, Clinton F. Stewart, Mark R. Gilbert, Richard Gilbertson, Amar Gajjar

*Corresponding author for this work

Research output: Contribution to journalArticle

30 Scopus citations

Abstract

Co-expression of ERBB2 and ERBB4, reported in 75 % of pediatric ependymomas, correlates with worse overall survival. Lapatinib, a selective ERBB1 and ERBB2 inhibitor has produced prolonged disease stabilization in patients with ependymoma in a phase I study. Bevacizumab exposure in ependymoma xenografts leads to ablation of tumor self-renewing cells, arresting growth. Thus, we conducted an open-label, phase II study of bevacizumab and lapatinib in children with recurrent ependymomas. Patients ≤21 years of age with recurrent ependymoma received lapatinib orally twice daily (900 mg/m2/dose to the first 10 patients, and then 700 mg/m2/dose) and bevacizumab 10 mg/kg intravenously on days 1 and 15 of a 28-day course. Lapatinib serum trough levels were analyzed prior to each course. Total and phosphorylated VEGFR2 expression was measured in peripheral blood mononuclear cells (PBMCs) before doses 1 and 2 of bevacizumab and 24–48 h following dose 2 of bevacizumab. Twenty-four patients with a median age of 10 years (range 2–21 years) were enrolled; 22 were eligible and 20 evaluable for response. Thirteen had anaplastic ependymoma. There were no objective responses; 4 patients had stable disease for ≥4 courses (range 4–14). Grade 3 toxicities included rash, elevated ALT, and diarrhea. Grade 4 toxicities included peri-tracheostomy hemorrhage (n = 1) and elevated creatinine phosphokinase (n = 1). The median lapatinib pre-dose trough concentration was 3.72 µM. Although the combination of bevacizumab and lapatinib was well tolerated in children with recurrent ependymoma, it proved ineffective.

Original languageEnglish (US)
Pages (from-to)85-91
Number of pages7
JournalJournal of Neuro-Oncology
Volume123
Issue number1
DOIs
StatePublished - May 26 2015

Keywords

  • Bevacizumab
  • Children
  • Lapatinib
  • Recurrent ependymoma

ASJC Scopus subject areas

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Fingerprint Dive into the research topics of 'An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN)'. Together they form a unique fingerprint.

  • Cite this

    DeWire, M., Fouladi, M., Turner, D. C., Wetmore, C., Hawkins, C., Jacobs, C., Yuan, Y., Liu, D., Goldman, S., Fisher, P., Rytting, M., Bouffet, E., Khakoo, Y., Hwang, E. I., Foreman, N., Stewart, C. F., Gilbert, M. R., Gilbertson, R., & Gajjar, A. (2015). An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN). Journal of Neuro-Oncology, 123(1), 85-91. https://doi.org/10.1007/s11060-015-1764-7